CN113614514B

CN113614514B - 6-phosphoglucose dehydrogenase mutant and application thereof in preparing detection reagent

Info

Publication number: CN113614514B
Application number: CN202080024000.9A
Authority: CN
Inventors: 龚俊; 肖兰萍; 祁金祥; 张启飞; 王贵利; 刘希
Original assignee: Beijing Strong Biotechnologies Inc
Current assignee: Beijing Strong Biotechnologies Inc
Priority date: 2020-01-07
Filing date: 2020-11-04
Publication date: 2022-11-25
Anticipated expiration: 2040-11-04
Also published as: US20230243819A1; CN113614514A; CN115856278B; CN115856278A; WO2021139375A1; JP2023509037A

Abstract

A 6-phosphoglucose dehydrogenase mutant and application thereof in preparing a detection reagent. The glucose-6-phosphate dehydrogenase mutant comprises a combination of the following mutations compared to the wild-type glucose-6-phosphate dehydrogenase: 56C, 306C and 454C. The detection kit prepared by using the glucose-6-phosphate dehydrogenase mutant has the advantages of strong specificity, high sensitivity, convenient operation, short detection time, accurate quantification and suitability for high-throughput detection.

Description

6-phosphoglucose dehydrogenase mutant and application thereof in preparing detection reagent

Technical Field

The application relates to the field of biological detection, in particular to a multi-site mutant enzyme, namely 6-phosphoglucose dehydrogenase (G6 PDH for short) and application thereof in a detection kit.

Background

Haptens, some small molecular substances (molecular weight less than 4000 Da), alone cannot induce an immune response, i.e. are not immunogenic, but can acquire immunogenicity when crosslinked or conjugated with carriers such as macromolecular proteins or non-antigenic polylysine, and induce an immune response. These small molecule substances can bind to response effector products, have antigenicity, are immunoreactive only and are not immunogenic, and are also called incomplete antigens.

The hapten can be combined with a corresponding antibody to generate an antigen-antibody reaction, and can not singly stimulate the human or animal body to generate the antigen of the antibody. It is immunoreactive only, has no immunogenicity, and is also called incomplete antigen. Most polysaccharides, lipids, hormones, and small molecule drugs are haptens. If a hapten is chemically conjugated to a protein molecule (carrier), it will acquire new immunogenicity and will stimulate the production of corresponding antibodies in animals.

Small molecule antigens (or haptens) lack two or more sites that can be used in sandwich assays and therefore cannot be measured using the double antibody sandwich method, and often use a competition mode. The principle is that the antigen in the sample and a certain amount of enzyme-labeled antigen compete for binding to the solid-phase antibody. The more the antigen content in the sample is, the less the enzyme-labeled antigen bound to the solid phase is, and the lighter the color development is. ELISA measurement of small molecule hormone, medicine, etc. is used in different methods.

The currently known hapten detection methods mainly comprise: radioimmunoassay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, high performance liquid chromatography, gas-liquid chromatography, gas chromatography, mass spectrometry, etc. However, these detection methods all have many defects, such as radioactive contamination of radioimmunoassay isotope, short validity period, inconvenient operation and the like, and the enzyme-linked immunosorbent assay is relatively complicated in operation, takes a long time and is not suitable for clinical use. Although the chemiluminescence has good sensitivity, the chemiluminescence needs special equipment, and the cost of the chemiluminescence is high, so that the chemiluminescence is not beneficial to popularization. In the clinical detection and diagnosis process, homogeneous enzyme immunoassay (EMIT) and latex enhanced immunoturbidimetry are mainly used for detection.

Principle of homogeneous enzyme immunoassay: in a liquid homogeneous reaction system, an enzyme-labeled antigen and a non-labeled antigen compete for being combined with a quantitative antibody, when the antibody is more combined with the non-labeled antigen, the more activity released by the enzyme-labeled antigen is, the more NADH is generated by catalyzing a substrate NAD +, and the absorbance change of NADH is detected under the wavelength of 340nm, so that the content of the hapten in the liquid can be calculated.

The prior art methods rely on the activation of reactive groups carried by the hapten (e.g., small molecule drug) itself, followed by reaction with an enzyme. Such a coupling method may cause a situation in which a plurality of small molecule drugs are linked to the same glucose-hexaphosphate dehydrogenase, and it is difficult to ensure consistency of coupling sites, and it is difficult to ensure orientation 1 between a small molecule drug and an enzyme: 1, resulting in large batch-to-batch variation.

Disclosure of Invention

In view of the need in the art, the present application provides a novel mutant of glucose-6-phosphate dehydrogenase, and its use in the preparation of a test agent.

According to some embodiments, a glucose-6-phosphate dehydrogenase mutant is provided. A glucose-6-phosphate dehydrogenase mutant of the present application comprising a combination of mutations selected from the group consisting of: 56C, 306C and 454C.

The mutants of the present application are distinguished from the glucose-6-phosphate dehydrogenase mutants of the patents listed, such as US006090567A (Homogeneous microorganisms using mutant glucose-6-phosphate dehydrogenes), and from the glucose-6-phosphate dehydrogenase mutants disclosed in CN110174363A as compared to the wild-type single mutants comprising D306C, D C or G426C.

According to some embodiments, there is provided a glucose-6-phosphate dehydrogenase mutant, the glucose-6-phosphate dehydrogenase mutant being represented by the following sequence: SEQ ID No.2.

According to some embodiments, there is provided a polynucleotide encoding a glucose-6-phosphate dehydrogenase mutant of the present application.

According to some embodiments, there is provided an expression vector comprising a polynucleotide of the present application.

According to some embodiments, there is provided a host cell comprising an expression vector of the present application. The host cell may be prokaryotic (e.g., bacteria) or eukaryotic (e.g., yeast).

According to some embodiments, there is provided a conjugate of a glucose-6-phosphate dehydrogenase mutant of the present application and a hapten in a molar ratio of 1: m is coupled.

In some embodiments, m is 1 to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.

In some specific embodiments, the glucose-6-phosphate dehydrogenase mutant of the present application is preferably present in a molar ratio of 1:3.

In some specific embodiments, the hapten has a molecular weight of from 100Da to 4000Da, for example: 100. 150, 200, 250, 300, 350, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 520, 550, 570, 600, 620, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000.

According to the present application, the skilled person will understand that "hapten" also comprises forms of its derivatives. To facilitate coupling to glucose-6-phosphate dehydrogenase, haptens that do not themselves have a coupling group (e.g., a group that reacts with a thiol group) can be engineered with a linker to covalently bind to a thiol group. Thus, in the present application, a hapten derivative refers to a hapten which has been engineered to carry a thiol-reactive group.

The hapten is selected from: small molecule drugs (e.g. antibiotics, psychotropic drugs), hormones, metabolites, sugars, lipids, amino acids, short peptides (molecular weight less than 4000kDa, or amino acids no longer than 50 amino acid residues in length).

Haptens, such as but not limited to:

-anti-cancer or anti-tumor drugs: taxane, paclitaxel and its derivatives, docetaxel, irinotecan, SN38, topotecan hydrochloride, topotecan, cisplatin, carboplatin, oxaliplatin, camptothecin and its derivatives, hydroxycamptothecin, vinblastine, vincristine, emetine hydrochloride, colchicine, doxorubicin, epirubicin, pirarubicin, valrubicin, doxorubicin or doxorubicin hydrochloride, epirubicin, daunorubicin, daunomycin, mitomycin, aclarubicin, idarubicin, bleomycin, pelomycin, mithramycin, rapamycin, disporubicin, streptozotocin, podophyllotoxin, actinomycin D, maytansinoid, amikacin, mitoxantrone, all-trans retinoic acid, vindesine, vinorelbine gemcitabine, capecitabine, cladribine, pemetrexed disodium, tegafur, letrozole, anastrozole, fulvestrant, goserelin, triptorelin, leuprolide, buserelin, temozolomide, cyclophosphamide, ifosfamide, gefitinib, sunitinib, erlotinib, lapatinib, sorafenib, imatinib, dasatinib, nilotinib, sirolimus, everolimus, mercaptopurine, methotrexate, 5-fluorouracil, dacarbazine, hydroxyurea, vorinostat, ixabepilone, bortezomib, cytarabine, etoposide, azacytidine, teniposide, propranolol, procaine, tetracaine, lidocaine, saratin, carmustine, chlorambucil, methylbenzylpyrazine, thiotepa;

antibiotics, antivirals, antifungals: <xnotran> , , E , , B, , , , B, , , , , , A, , , , , , , , G, V, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 3238 zxft 3238 , , , A, , , , , , , , , , , , , , , , , , , , , , , , , , , 3262 zxft 3262, , , , , , , , , , , , , , , </xnotran> <xnotran> , , , , , , , , , , , , , , , , , , , , , , , , , , , 5363 zxft 5363, , , , , , , , , , , , , , , , , , II, , , , , , , , , , , , , , , , , , , , , , , , , A, ; </xnotran>

-cytochalasin B, aminomethylbenzoic acid, paminonuronic acid, pamidronic acid, amsacrine, anagrelide, anastrozole, levamisole, busulfan, cabergoline, willowalin, cilastatin sodium, disodium clodronate, amiodarone, ondansetron, descycloleprosone, megestrol, testosterone, estramustine, exemestane, fluoroxymethyltestosterone, diethylstilbestrol, fexofenadine, fludarabine, fludrocortisone, fluticasone, deferoxamine, flutamide, bicalutamide, thalidomide, L-dopa, leucovorin, lisinopril, levothyroxine sodium, azacitidine, luteolin, metahydroxydesmethylephedrine ditartrate, meclizine, mitotane, nilutamide, olptin, oxytetracycline, pentamycin, porphinidin, porphine, phenoxathiin, porphine, mepiquin, and porphin prednisone, procarbazine, pra Lu Lv piperazine, letrothiin, streptozotocin, sirolimus, tacrolimus, tamoxifen, teniposide, tetrahydrocannabinol, thioguanine, thiotepa, dolasetron, granisetron, formoterol, melphalan, midazolam, alprazolam, sumatriptan, low molecular weight heparin, amifostine, carmustine, gemcitabine, lomustine, tafosstine, aspirin, salicylic acid, phenylbutazone, indomethacin, naproxen, diclofenac, meloxicam, nabumetone, etodolac, sulindac, acemetacin, amdoxovir, cyanuric blue, aminoarone, aminocaproic acid, aminoglutethimide, aminolevulinic acid, butanediol mesylate, clodronate, disodium clodronate, L-dihydroxyphenylalanine, dichloromethyl diethylamine, m-hydroxylamine bitartrate, o-dichlorobenzene dichloroethane, prochlorperazine, ondansetron, raltitrexed, tacromem, tamoxifen, teniposide, tetrahydrocannabinol, aroylhydrazone, sumatriptan, mexicamin, spiramycin, benzene mustard cholesterol, piposulfan, epinastine hydrochloride, insulin, antisense nucleotides, small RNA molecules, and the like,

-vitamin D, 25 hydroxyvitamin D, 1, 25 dihydroxyvitamin D, folic acid, cardiac glycoside, mycophenolic acid, amiodarone, methotrexate, tacrolimus, serum amino acids, bile acids, glycocholic acid, phenylalanine, ethanol, metabolites of nicotifen, uromorphine, derivatives of urotensin, neuropeptide tyrosine, plasma galanin, polyamines, histamine, thyroid stimulating hormone, prolactin, placental prolactin, growth hormone, follicle stimulating hormone, luteinizing hormone, adrenocorticotropic hormone, antidiuretic hormone, calcitonin, procalcitonin, parathyroid hormone, thyroxine, triiodothyronine, free thyroxine, free triiodothyronine, cortisol, urinary 17-hydroxycorticoids, pharmaceutical compositions containing said compounds, and methods of use urinary 17-ketosteroids, dehydroepiandrosterone and sulfate esters, aldosterone, urovanillyl mandelic acid, plasma renin, angiotensin, erythropoietin, testosterone, dihydrotestosterone, androstenedione, 17 alpha hydroxyprogesterone, estrone, estriol, estradiol, progesterone, human chorionic gonadotropin, insulin, proinsulin, C-peptide, gastrin, plasma prostaglandin, plasma 6-one prostaglandin F1 alpha, prostacyclin, epinephrine, catecholamine, norepinephrine, cholecystokinin, nalin, adenosine cyclophosphate, guanosine cyclophosphate, vasoactive peptides, somatostatin, secretin, P-substance, neurotensin, thromboxane A2, thromboxane B2, 5 hydroxytryptamine, neuropeptide Y, osteocalcin.

In a particular embodiment, the hapten is tobramycin or a derivative thereof.

Although tobramycin is given as a specific example, the skilled person will appreciate that the technical effect of the present application is independent of the particular type of hapten, and is applicable to any hapten which can be immunologically detected by means of competition.

In particular embodiments, the hapten is a tobramycin derivative which carries a thiol-reactive group, such as, for example, a maleimide, bromoacetyl, vinyl sulfone, or aziridine.

In a particular embodiment, the hapten is a tobramycin derivative, represented by formula I:

m is an integer from 0 to 20, preferably an integer from 1 to 10, preferably an integer from 1 to 6;

x is selected from: maleimide, bromoacetyl, vinyl sulfone, aziridine;

more preferably, X is maleimide.

In a particular embodiment, the hapten is a tobramycin derivative, as shown in formula II:

according to some embodiments, there is provided a reagent comprising a conjugate of the present application.

According to some embodiments, there is provided the use of a glucose-6-phosphate dehydrogenase mutant of the present application in the preparation of a test agent.

According to some embodiments, there is provided the use of a conjugate of the present application in the preparation of a detection reagent.

In specific embodiments, the detection reagent is selected from the group consisting of: enzyme-linked immunosorbent assay reagent, chemiluminescence immunoassay reagent, homogeneous enzyme immunoassay reagent and latex enhanced immunoturbidimetry reagent.

In a specific embodiment, the detection reagent is preferably a reagent for detection based on a competition method.

According to some embodiments, there is provided a hapten detection kit comprising:

-a first reagent comprising a substrate and a hapten antibody; the substrate is a substrate for glucose-6-phosphate dehydrogenase;

-a second agent comprising a conjugate of the present application;

-optionally, a calibrator comprising 10mM to 500mM buffer and hapten; and

-optionally, a quality control comprising 10mM to 500mM buffer and hapten.

According to one embodiment, there is provided a hapten detection kit comprising:

a first reagent comprising:

10mM to 500mM buffer solution,

5mM to 25mM substrate,

0.01 mu g/L to 1mg/L of hapten antibody,

10mM to 300mM NaCl,

0.1 to 5g/L stabilizer,

0.1g/L to 5g/L of surfactant,

0.1g/L to 5g/L preservative;

a second reagent comprising:

10mM to 500mM buffer solution,

0.01 μ g/L to 1mg/L of a conjugate of the present application,

0.1 to 5g/L stabilizer,

0.1g/L to 5g/L of surfactant,

0.1g/L to 5g/L preservative.

According to some specific embodiments, there is provided a tobramycin detection kit comprising:

-a first reagent comprising a substrate and a tobramycin antibody; the substrate is a substrate for glucose-6-phosphate dehydrogenase;

-a second agent comprising a conjugate of the present application;

-optionally, a calibrator comprising a buffer of 10mM to 500mM, a known concentration of tobramycin; and

-optionally, a quality control comprising a buffer of 10mM to 500mM, a known concentration of tobramycin.

According to one embodiment, there is provided a tobramycin detection kit comprising:

a first reagent comprising:

10mM to 500mM buffer solution,

5mM to 25mM substrate,

0.01 to 10 mug/ml tobramycin antibody,

10mM to 300mM NaCl,

0.1 to 5g/L stabilizer,

0.1g/L to 5g/L of surfactant,

0.1g/L to 5g/L preservative;

a second reagent comprising:

10mM to 500mM buffer solution,

0.01 μ g/ml to 10 μ g/ml of a conjugate of the present application,

0.1 to 5g/L stabilizer,

0.1g/L to 5g/L of surfactant,

0.1g/L to 5g/L preservative.

In some embodiments, the buffer is selected from one or a combination of: tromethamine buffer solution, phosphate buffer solution, tris-HCl buffer solution, citric acid-sodium citrate buffer solution, barbital buffer solution, glycine buffer solution, borate buffer solution and trimethylolmethane buffer solution; preferably, a phosphate buffer; the concentration of the buffer solution is 10mmol/L to 500mmol/L, preferably 100mM; the pH of the buffer is 6.5 to 8.0, preferably 7.2 or 7.0.

In some embodiments, the stabilizing agent is selected from one or a combination of: bovine serum albumin, trehalose, glycerol, sucrose, mannitol, glycine, arginine, polyethylene glycol 6000, polyethylene glycol 8000; bovine serum albumin is preferred.

In some embodiments, the surfactant is selected from one or a combination of: brij23, brij35, triton X-100, triton X-405, tween20, tween30, tween80, coconut oil fatty acid diethanolamide, AEO7, preferably Tween20.

In some embodiments, the preservative is selected from one or a combination of: azide, MIT, PC-300, thimerosal; the azide is selected from: sodium azide and lithium azide.

In some embodiments, the substrate comprises: 6-phosphoglucose, beta-nicotinamide adenine dinucleotide.

According to some embodiments, there is provided a method of preparing a conjugate comprising the steps of:

1) Providing a hapten or a derivative thereof according to the present application, in particular in an aprotic solvent (such as but not limited to acetonitrile, dimethylformamide, dimethylsulfoxide);

2) Providing a glucose-6-phosphate dehydrogenase mutant of the present application, preferably in a buffer (which provides a reaction environment, such as, but not limited to, PBS, tris, TAPS, TAPSO, the buffer pH being 6.0 to 8.0);

3) (ii) contacting the glucose-6-phosphate dehydrogenase mutant and the hapten or derivative thereof in a molar ratio of 1: n for 1 to 4 hours (preferably 2 to 3 hours) to allow the hapten or derivative thereof and the glucose-6-phosphate dehydrogenase mutant to be conjugated to obtain the seed conjugate;

4) The conjugate is optionally subjected to purification, such as desalting treatment or the like, as required.

In some embodiments, n is 1 to 500, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500 or a range between any number.

In some specific embodiments, the glucose-6-phosphate dehydrogenase mutant and the hapten or derivative thereof are present in a molar ratio of 1:30 to 1:120 contact, mention may be made of 1: 30. 1: 40. 1: 50. 1: 60. 1: 70. 1: 80. 1: 90. 1: 100. 1: 110. or 1:120.

in some specific embodiments, steps 1) and 2) are interchangeable or concurrent.

In some specific embodiments, the glucose-6-phosphate dehydrogenase, prior to conjugation, comprises a free sulfhydryl group, thereby allowing for 1:3, directional reaction.

Drawings

FIG. 1.G6PDH (wild-type) amino acid sequence (SEQ ID No. 1); derived from Leuconostoc pseudomesenteroides of Leuconostoc.

FIG. 2 G6PDH mutant (SEQ ID No. 2).

Detailed Description

Examples

Example 1 Synthesis of Tobramycin derivatives

Tobramycin (98mg, 0.21mmol) and compound 1 (64mg, 0.21mmol) were dissolved in 5mL of water and stirred at room temperature for 5h. HPLC separation to obtain tobramycin derivative. The synthetic route is as follows:

the structure of the composition was confirmed by a conventional method. The effect of this example is to make small molecule antigens (or haptens) with a group that can bind to enzymes, and the technical effect of this application is independent of the particular hapten derivative.

Example 2 preparation of mutants

The enzyme mutant represented by SEQ ID No.2 is obtained by a known genetic engineering method, for example, synthesizing a desired DNA, inserting into an appropriate expression vector (e.g., an E.coli expression vector), expressing in an expression host, and purifying (e.g., affinity purification).

Example 3 coupling of Tobramycin derivatives to G6PDH mutants

The coupling was carried out according to the G6 PDH-tobramycin conjugate of the application in the following manner: a thiol-reactive group (e.g., a maleimide group) on the tobramycin derivative molecule is covalently bonded to a thiol on the G6PDH molecule.

A solution of the G6PDH enzyme mutant of example 2 (or a control G6PDH enzyme mutant of the prior art) (5 mg/mL enzyme, 100mmol PB, 100mmol NaCl, pH = 8.0) was reacted with 4. Mu.l, 200. Mu.l PB solution, 800. Mu.l of the tobramycin derivative prepared in example 1 at room temperature (18 to 28 ℃, preferably 20 to 25 ℃) with shaking for 2.5h.

Desalting column treatment (desalting solution 100mM PB, 0.1% NaN3, 1% NaCl, pH = 8.0), protein peak collection, G6 PDH-tobramycin conjugate.

Example 4 preparation of the kit

A kit for detecting tobramycin is prepared comprising:

1. preparation of the first reagent:

2. preparation of the second reagent:

3. calibration products:

the tobramycin pure product is obtained by diluting with buffer solution (100 mM HEPES buffer solution) to obtain the pure product with the concentrations of 0, 0.6, 2.0, 4.0, 6.0 and 10.0mg/L (or adding according to needs);

4. quality control product:

the tobramycin pure product was diluted with a buffer solution (100 mM HEPES buffer) to give concentrations of 1.5mg/L, 3mg/L, and 8mg/L, respectively (or added as required).

Example of detection

TABLE 1 parameters of fully automatic biochemical analyzer

Detection example 1 calibration of Absorbance of Tobramycin assay kit

TABLE 2 Tobramycin assay kit calibration Absorbance

Detection example 2 Tobramycin assay kit reproducibility

And repeatedly measuring the high-quality control product, the medium-quality control product and the low-quality control product for 20 times respectively. The repeatability CV of the kit is below 2.61 percent, and the repeatability is better.

TABLE 3 repeatability

Number of times of measurement	Quality control	1	Quality control 2	Quality control 3
					1	1.62	2.89	8.10
2	1.67	2.85	8.13
				3	1.65	2.86	8.04
4	1.64	2.89	8.01
				5	1.67	2.89	8.28
6	1.60	2.82	8.35
				7	1.62	2.82	8.19
8	1.56	2.82	8.09
				9	1.62	2.84	8.17
10	1.59	2.88	8.25
				11	1.55	2.81	8.04
12	1.58	2.83	8.17
				13	1.66	2.85	8.03
14	1.59	2.84	8.06
				15	1.51	2.87	8.28
16	1.58	2.85	8.16
				17	1.61	2.86	7.94
18	1.57	2.75	8.02
				19	1.59	2.77	8.15
20	1.58	2.85	8.10
				Mean value	1.60	2.84	8.13
STD	0.04	0.04	0.11
				CV	2.61％	1.31％	1.30％

Detection example 3. Tobramycin assay kit Linearity

And (3) screening low-value samples and high-value samples, diluting according to an equal difference dilution method, repeatedly detecting each sample for 3 times, carrying out recovery rate analysis on the average value of the measured concentration and the theoretical concentration, wherein the result deviation is less than 10%, and the linearity can reach 10 mu g/ml.

TABLE 4 linearity

Detection example 4 accuracy

The pure product of the tobramycin in the United states pharmacopoeia is dissolved into stock solutions with different concentrations, the stock solutions are diluted into serum by the same times (the dilution times are at least 20 times), serum tobramycin solutions with different concentrations are prepared, the deviation from a theoretical value is measured and calculated by using the kit, the deviation of the result recovery rate is less than 6%, and the accuracy is good.

TABLE 5 accuracy

USP	Measured value 1	Measured value 2	Measured value 3	Mean value	Absolute deviation	Relative deviation of
							1.00	1.06	1.08	1.04	1.06	0.06	6.00％
1.50	1.59	1.52	1.51	1.54	0.04	2.67％
							2.00	2.02	1.98	2.04	2.01	0.01	0.67％
4.00	3.04	2.94	2.97	2.98	-0.02	-0.56％
							8.00	5.09	4.95	4.99	5.01	0.01	0.20％
10.00	10.12	10.01	10.05	10.06	0.06	0.60％

Detection example 5 antibody inhibition Rate

1. Detection principle of antibody inhibition rate

When the antibody is combined with the G6 PDH-tobramycin conjugate, the activity of G6PDH enzyme is influenced due to steric hindrance, so that the efficiency of catalyzing NAD to be converted into NADH is reduced, and the difference between an experimental group with the antibody added and an experimental group without the antibody added is compared by detecting the change of NADH amount, wherein the difference is represented by the inhibition capacity of the antibody on G6 PDH.

2. Reaction system:

TABLE 6 preparation of reagents for detection of antibody inhibition

TABLE 7 antibody inhibition Rate testing of on-machine parameters

Detecting machine type	Hitachi 7180
		analysis/time/Point	2 point speed/10 min/10-15 points
R1/S	150:25
		Wavelength (auxiliary/main)	405/340
Type of reaction	Incremental increase

3. As a result:

and comparing the added antibody with the unadditized antibody, and respectively detecting the absorbance value of the G6 PDH-tobramycin conjugate to obtain the inhibition of the antibody on G6 PDH.

Where Δ a refers to the difference in absorbance between the two test time points of the reaction curve.

TABLE 8 antibody inhibition of different G6PDH mutants

While not being bound to a particular theory, it may be partially explained as: compared with the G6PDH mutant in the prior art, the mutant (K56C/D306C/D454C) of the enzyme of the application has a mutation site (i.e. a site for introducing a free sulfydryl) at a position for coupling with a hapten (such as hormone, small molecule drug and the like). When the hapten binds to a hapten-specific antibody at this position, the steric hindrance formed has the greatest effect on the activity of the G6PDH enzyme, and after the introduction of the mutation, it cannot substantially affect the steric folding of the molecule. Therefore, the position of this mutation site is very important, and needs to be compatible with the activity of G6PDH enzyme, the spatial folding of the coupling molecule, and the sufficient exposure of the hapten epitope.

The enzyme mutant has obvious improvement on the antibody inhibition rate and can have obvious advantage on calibration absorbance. After the conjugate obtained by coupling the enzyme mutant and the hapten is prepared into the kit, the reagent has obvious performance improvement in the aspects of repeatability, total inaccuracy, linearity, specificity and the like.

Sequence listing

<110> Beijing Jiuqiang Biotechnology Ltd

<120> 6-phosphoglucose dehydrogenase mutant and application thereof in preparation of detection reagent

<130> 390311CG

<160> 2

<170> SIPOSequenceListing 1.0

<210> 1

<211> 486

<212> PRT

<213> Leuconostoc pseudomesenteroides (Leuconostoc pseudosensoides)

<400> 1

Met Val Ser Glu Ile Lys Thr Leu Val Thr Phe Phe Gly Gly Thr Gly

1 5 10 15

Asp Leu Ala Lys Arg Lys Leu Tyr Pro Ser Val Phe Asn Leu Tyr Lys

20 25 30

Lys Gly Tyr Leu Gln Lys His Phe Ala Ile Val Gly Thr Ala Arg Gln

35 40 45

Ala Leu Asn Asp Asp Glu Phe Lys Gln Leu Val Arg Asp Ser Ile Lys

50 55 60

Asp Phe Thr Asp Asp Gln Ala Gln Ala Glu Ala Phe Ile Glu His Phe

65 70 75 80

Ser Tyr Arg Ala His Asp Val Thr Asp Ala Ala Ser Tyr Ala Val Leu

85 90 95

Lys Glu Ala Ile Glu Glu Ala Ala Asp Lys Phe Asp Ile Asp Gly Asn

100 105 110

Arg Ile Phe Tyr Met Ser Val Ala Pro Arg Phe Phe Gly Thr Ile Ala

115 120 125

Lys Tyr Leu Lys Ser Glu Gly Leu Leu Ala Asp Thr Gly Tyr Asn Arg

130 135 140

Leu Met Ile Glu Lys Pro Phe Gly Thr Ser Tyr Asp Thr Ala Ala Glu

145 150 155 160

Leu Gln Asn Asp Leu Glu Asn Ala Phe Asp Asp Asn Gln Leu Phe Arg

165 170 175

Ile Asp His Tyr Leu Gly Lys Glu Met Val Gln Asn Ile Ala Ala Leu

180 185 190

Arg Phe Gly Asn Pro Ile Phe Asp Ala Ala Trp Asn Lys Asp Tyr Ile

195 200 205

Lys Asn Val Gln Val Thr Leu Ser Glu Val Leu Gly Val Glu Glu Arg

210 215 220

Ala Gly Tyr Tyr Asp Thr Ala Gly Ala Leu Leu Asp Met Ile Gln Asn

225 230 235 240

His Thr Met Gln Ile Val Gly Trp Leu Ala Met Glu Lys Pro Glu Ser

245 250 255

Phe Thr Asp Lys Asp Ile Arg Ala Ala Lys Asn Ala Ala Phe Asn Ala

260 265 270

Leu Lys Ile Tyr Asp Glu Ala Glu Val Asn Lys Tyr Phe Gly Arg Ala

275 280 285

Gln Tyr Gly Ala Gly Asp Ser Ala Asp Phe Lys Pro Tyr Leu Glu Glu

290 295 300

Leu Asp Val Pro Ala Asp Ser Lys Asn Asn Thr Phe Ile Ala Gly Glu

305 310 315 320

Leu Gln Phe Asp Leu Pro Arg Trp Glu Gly Val Pro Phe Tyr Val Arg

325 330 335

Ser Gly Lys Arg Leu Ala Ala Lys Gln Thr Arg Val Asp Ile Val Phe

340 345 350

Lys Ala Gly Thr Phe Asn Phe Gly Ser Glu Gln Glu Ala Gln Glu Ala

355 360 365

Val Leu Ser Ile Ile Ile Asp Pro Lys Gly Ala Ile Glu Leu Lys Leu

370 375 380

Asn Ala Lys Ser Val Glu Asp Ala Phe Asn Thr Arg Thr Ile Asp Leu

385 390 395 400

Gly Trp Thr Val Ser Asp Glu Asp Lys Lys Asn Thr Pro Glu Pro Tyr

405 410 415

Glu Arg Met Ile His Asp Thr Met Asn Gly Asp Gly Ser Asn Phe Ala

420 425 430

Asp Trp Asn Gly Val Ser Ile Ala Trp Lys Phe Val Asp Ala Ile Ser

435 440 445

Ala Val Tyr Thr Ala Asp Lys Ala Pro Leu Glu Thr Tyr Lys Ser Gly

450 455 460

Ser Met Gly Pro Glu Ala Ser Asp Lys Leu Leu Ala Ala Asn Gly Asp

465 470 475 480

Ala Trp Val Phe Lys Gly

485

<210> 2

<211> 486

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> VARIANT

<222> (56)..(56)

<223> G6PDH mutant, amino acid substitution at position 56 to C compared to wild type

<220>

<221> VARIANT

<222> (306)..(306)

<223> G6PDH mutant, amino acid substitution at position 306 to C compared to wild type

<220>

<221> VARIANT

<222> (454)..(454)

<223> G6PDH mutant, substitution of amino acid at position 454 to C as compared with wild type

<400> 2

Met Val Ser Glu Ile Lys Thr Leu Val Thr Phe Phe Gly Gly Thr Gly

1 5 10 15

Asp Leu Ala Lys Arg Lys Leu Tyr Pro Ser Val Phe Asn Leu Tyr Lys

20 25 30

Lys Gly Tyr Leu Gln Lys His Phe Ala Ile Val Gly Thr Ala Arg Gln

35 40 45

Ala Leu Asn Asp Asp Glu Phe Cys Gln Leu Val Arg Asp Ser Ile Lys

50 55 60

Asp Phe Thr Asp Asp Gln Ala Gln Ala Glu Ala Phe Ile Glu His Phe

65 70 75 80

Ser Tyr Arg Ala His Asp Val Thr Asp Ala Ala Ser Tyr Ala Val Leu

85 90 95

Lys Glu Ala Ile Glu Glu Ala Ala Asp Lys Phe Asp Ile Asp Gly Asn

100 105 110

Arg Ile Phe Tyr Met Ser Val Ala Pro Arg Phe Phe Gly Thr Ile Ala

115 120 125

Lys Tyr Leu Lys Ser Glu Gly Leu Leu Ala Asp Thr Gly Tyr Asn Arg

130 135 140

Leu Met Ile Glu Lys Pro Phe Gly Thr Ser Tyr Asp Thr Ala Ala Glu

145 150 155 160

Leu Gln Asn Asp Leu Glu Asn Ala Phe Asp Asp Asn Gln Leu Phe Arg

165 170 175

Ile Asp His Tyr Leu Gly Lys Glu Met Val Gln Asn Ile Ala Ala Leu

180 185 190

Arg Phe Gly Asn Pro Ile Phe Asp Ala Ala Trp Asn Lys Asp Tyr Ile

195 200 205

Lys Asn Val Gln Val Thr Leu Ser Glu Val Leu Gly Val Glu Glu Arg

210 215 220

Ala Gly Tyr Tyr Asp Thr Ala Gly Ala Leu Leu Asp Met Ile Gln Asn

225 230 235 240

His Thr Met Gln Ile Val Gly Trp Leu Ala Met Glu Lys Pro Glu Ser

245 250 255

Phe Thr Asp Lys Asp Ile Arg Ala Ala Lys Asn Ala Ala Phe Asn Ala

260 265 270

Leu Lys Ile Tyr Asp Glu Ala Glu Val Asn Lys Tyr Phe Val Arg Ala

275 280 285

Gln Tyr Gly Ala Gly Asp Ser Ala Asp Phe Lys Pro Tyr Leu Glu Glu

290 295 300

Leu Cys Val Pro Ala Asp Ser Lys Asn Asn Thr Phe Ile Ala Gly Glu

305 310 315 320

Leu Gln Phe Asp Leu Pro Arg Trp Glu Gly Val Pro Phe Tyr Val Arg

325 330 335

Ser Gly Lys Arg Leu Ala Ala Lys Gln Thr Arg Val Asp Ile Val Phe

340 345 350

Lys Ala Gly Thr Phe Asn Phe Gly Ser Glu Gln Glu Ala Gln Glu Ala

355 360 365

Val Leu Ser Ile Ile Ile Asp Pro Lys Gly Ala Ile Glu Leu Lys Leu

370 375 380

Asn Ala Lys Ser Val Glu Asp Ala Phe Asn Thr Arg Thr Ile Asp Leu

385 390 395 400

Gly Trp Thr Val Ser Asp Glu Asp Lys Lys Asn Thr Pro Glu Pro Tyr

405 410 415

Glu Arg Met Ile His Asp Thr Met Asn Gly Asp Gly Ser Asn Phe Ala

420 425 430

Asp Trp Asn Gly Val Ser Ile Ala Trp Lys Phe Val Asp Ala Ile Ser

435 440 445

Ala Val Tyr Thr Ala Cys Lys Ala Pro Leu Glu Thr Tyr Lys Ser Gly

450 455 460

Ser Met Gly Pro Glu Ala Ser Asp Lys Leu Leu Ala Ala Asn Gly Asp

465 470 475 480

Ala Trp Val Phe Lys Gly

485

Claims

1. A conjugate of a glucose-6-phosphate dehydrogenase mutant and a tobramycin derivative in a molar ratio of 1:1 to 1:3, coupling to obtain;

the glucose-6-phosphate dehydrogenase mutant comprises a combination of the following mutations, compared to the wild-type glucose-6-phosphate dehydrogenase of Leuconostoc pseudomesenteroides: 56C, 306C, and 454C;

the tobramycin derivative is represented by formula I:

formula I

m is an integer of 0 to 20;

x is selected from any one or more of: maleimide, bromoacetyl, vinyl sulfone, aziridine;

the 6-phosphoglucose dehydrogenase mutant is shown as SEQ ID No.2.

2. The conjugate of claim 1, wherein the molar ratio is 1:3.

3. the conjugate of claim 1, wherein m is an integer from 1 to 10.

4. The conjugate of claim 1, wherein m is an integer from 1 to 6.

5. The conjugate of claim 1, wherein X is maleimide.

6. An agent comprising the conjugate of any one of claims 1 to 5.

7. Use of a conjugate according to any one of claims 1 to 5 in the manufacture of a test device, wherein the test device is a tobramycin-directed test device.

8. Use according to claim 7, the device being an enzyme-linked immunoassay device.

9. The use according to claim 7, wherein the device to be tested is a chemiluminescent immunoassay device.

10. The use according to claim 7, wherein the device is a homogeneous enzyme immunoassay device.

11. The use according to claim 7, wherein the device is a latex-enhanced immunoturbidimetry device.

12. The use according to claim 7, the detection device being a kit.

13. Use according to claim 7, the device to be tested being a well plate.

14. The use according to claim 7, wherein the device to be tested is a test strip.

15. Use according to claim 7, the means to be detected being magnetic beads.

16. Use according to claim 7, the device to be detected being latex particles.

17. Use according to claim 7, the device to be tested being a chip.

18. A method of preparing a conjugate comprising the steps of:

1) Providing a glucose-6-phosphate dehydrogenase mutant;

2) Providing a hapten;

3) The glucose-6-phosphate dehydrogenase mutant and the hapten are mixed according to a molar ratio of 1:3 forming a coupling;

step 1) and step 2) are parallel or in an interchangeable order;

the hapten is a tobramycin derivative;

the tobramycin derivative is represented by formula I:

formula I

m is an integer of 0 to 20;

the glucose 6-phosphate dehydrogenase mutant comprises a combination of the following mutations compared to a wild-type glucose 6-phosphate dehydrogenase of Leuconostoc pseudomesenteroides: 56C, 306C, and 454C;

the 6-phosphoglucose dehydrogenase mutant is shown as SEQ ID No.2.

19. The method of preparing a conjugate according to claim 18, wherein m is an integer from 1 to 10.

20. The method of preparing a conjugate according to claim 18, wherein m is an integer from 1 to 6.

21. The method of preparing a conjugate according to claim 18, wherein X is maleimide.

22. The method for preparing a conjugate according to claim 18, wherein the step 3) is performed under the following conditions:

(ii) reacting the glucose-6-phosphate dehydrogenase mutant and the hapten at 18 ℃ to 28 ℃ in a ratio of 1:30 to 1:120 for 1 to 4 hours.

23. The method of preparing a conjugate according to claim 18, wherein:

providing the glucose-6-phosphate dehydrogenase mutant in a buffer in step 1);

in step 2), providing the hapten in an aprotic solvent;

the buffer is selected from any one of the following: PBS, tris, TAPS, TAPSO,

the buffer pH is 6.0 to 8.0;

the aprotic solvent is selected from any one or combination of: acetonitrile, dimethylformamide, dimethyl sulfoxide.

24. The method of preparing a conjugate of claim 18, further comprising the steps of:

4) The resulting conjugate was desalted.